The Black Straight-Line Sign in the Putamen in Diffusion-Weighted Imaging: A Potential Diagnostic MRI Marker for Multiple System Atrophy

Background and PurposeThe diagnosis of multiple system atrophy (MSA) remains challenging in clinical practice. This study investigated the value of hypointense signals in the putamen (black straight-line sign) in diffusion-weighted imaging (DWI) of brain MRI for distinguishing (MSA) from Parkinson's disease (PD). MethodsWe retrospectively enrolled 30 MSA patients, 30 PD patients, and 30 healthy controls who had undergone brain MRI between 2016 and 2020. Two readers independently assessed the signal intensity of the bilateral putamen on DWI. The putaminal hypointensity was scored using 4-point visual scales. Putaminal hypointensity and the presence of a black straight-line sign were statistically compared between MSA and PD or healthy controls. ResultsThe mean scores of putaminal hypointensity in DWI in the MSA group were significantly higher than in both the PD (U = 315.5, P = 0.034) and healthy control groups (U = 304.0, P = 0.022). Uni- or bilateral putaminal hypointensity in DWI with a score >= 2 was identified in 53.3% (16/30), 16.7% (5/30), and 13.3% (4/30) of MSA, PD, and healthy controls, respectively, with significant differences between MSA and PD (X-2 = 8.864, P = 0.003) or healthy controls (X-2 = 10.800, P = 0.001). Notably, the black straight-line sign of the putamen was observed in 16/30 (sensitivity 53.3%) patients with MSA, while it was absent in PD and healthy controls (specificity 100%). There were no significant differences for the presence of black straight-line sign in the MSA-P and MSA-C groups (X-2 = 0.433, P = 0.510). ConclusionThe black straight-line sign of the putamen in DWI of head MRIs has the potential to serve as a diagnostic marker for distinguishing MSA from PD.

Automated summary

The black straight-line sign in diffusion-weighted imaging (DWI) of the putamen in head MRIs has the potential to serve as a diagnostic marker for distinguishing multiple system atrophy (MSA) from Parkinson's disease (PD).